

Vasco C Romão

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5078532/publications.pdf>

Version: 2024-02-01

56
papers

1,791
citations

393982

19
h-index

301761

39
g-index

60
all docs

60
docs citations

60
times ranked

2647
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and ultrasonographic features of erythema nodosum in Behçet's disease. <i>Rheumatology</i> , 2022, 61, e254-e254.	0.9	1
2	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
3	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.5	12
4	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
5	Angiotensin-Converting Enzyme Activity May Predict Disease Severity in Psoriasis. <i>Rheumato</i> , 2022, 2, 15-23.	0.2	1
6	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
7	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 32-39.	0.4	3
8	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
9	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
10	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
11	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
12	No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e22-e22.	0.5	12
13	Response to: "The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients" by Favalli et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e76-e76.	0.5	1
14	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
15	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	6.3	145
16	Late presentation of macrodystrophia lipomatosa—a rare, impressive diagnosis. <i>Rheumatology</i> , 2021, 61, 469-470.	0.9	1
17	A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 695-704.	1.1	8
18	Neurologic Manifestations of the Antiphospholipid Syndrome—an Update. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 41.	2.0	26

#	ARTICLE	IF	CITATIONS
19	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	0.9	22
20	Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. <i>Frontiers in Medicine</i> , 2021, 8, 689698.	1.2	47
21	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
22	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 57-65.	0.4	13
23	Efficacy, Safety, and Sample Quality of Ultrasound-Guided Synovial Needle Biopsy in Clinical Practice and Research: A Prospective Observational Study. <i>Arthritis Care and Research</i> , 2020, 72, 1497-1505.	1.5	14
24	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.5	307
25	Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. <i>Rheumatology</i> , 2020, 59, .	0.9	1
26	Celastrol Efficacy by Oral Administration in the Adjuvant-Induced Arthritis Model. <i>Frontiers in Medicine</i> , 2020, 7, 455.	1.2	10
27	Elderly-onset rheumatoid arthritis is a unique disease subset associated with poor overall outcomes: Response to the letter by Haroon and Ayamer. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 51, e11-e12.	1.6	0
28	Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. <i>RMD Open</i> , 2020, 6, e001314.	1.8	19
29	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 735-743.	1.6	15
30	A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 576162.	1.2	7
31	Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?. <i>Frontiers in Medicine</i> , 2019, 6, 144.	1.2	18
32	Anti-TNF Drugs for Chronic Uveitis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Medicine</i> , 2019, 6, 104.	1.2	21
33	Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome. <i>Lupus</i> , 2019, 28, 27-33.	0.8	10
34	Loss to follow-up in registries of rheumatic patients treated with biologics: a potential information bias in assessing pharmacovigilance and efficacy outcomes. <i>Acta Reumatologica Portuguesa</i> , 2019, 44, 281-287.	0.2	0
35	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis: a systematic review. <i>Acta Ophthalmologica</i> , 2018, 96, e665-e675.	0.6	20
36	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 702-710.	2.9	32

#	ARTICLE	IF	CITATIONS
37	The Ratio of Blood T Follicular Regulatory Cells to T Follicular Helper Cells Marks Ectopic Lymphoid Structure Formation While Activated Follicular Helper T Cells Indicate Disease Activity in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 774-784.	2.9	94
38	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 1355-1356.	2.9	0
39	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	1.6	29
40	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	1.8	34
41	T Follicular Regulatory Cells Are Decreased in Patients With Established Treated Rheumatoid Arthritis With Active Disease: Comment on the Article by Liu et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 1893-1895.	2.9	14
42	Human blood T cells are indicators of ongoing humoral activity not fully licensed with suppressive function. <i>Science Immunology</i> , 2017, 2, .	5.6	119
43	B-cell phenotype and igd-cd27- memory b cells are affected by tnf-inhibitors and tocilizumab treatment in rheumatoid arthritis. , 2017, , .		0
44	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2017, 19, 239.	1.6	38
45	B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0182927.	1.1	72
46	Efficacy and Safety of Vaccination in Pediatric Patients with Systemic Inflammatory Rheumatic Diseases: a systematic review of the literature. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 8-16.	0.2	7
47	Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 324-328.	0.2	4
48	Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register. <i>Rheumatology International</i> , 2016, 36, 955-960.	1.5	44
49	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016, 2, e000240.	1.8	14
50	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	19
51	Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 1180-1185.	1.5	125
52	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. <i>Lupus</i> , 2015, 24, 256-262.	0.8	26
53	Synovial heterogeneity in rheumatoid arthritis: the key for rational patient stratification?. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 6-8.	0.2	5
54	Saber Tibia in Paget's Disease of Bone. <i>New England Journal of Medicine</i> , 2014, 371, 2417-2417.	13.9	4

#	ARTICLE	IF	CITATIONS
55	Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?. Immunologic Research, 2014, 60, 289-310.	1.3	91
56	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. BMC Medicine, 2013, 11, 17.	2.3	71